HC Wainwright Reaffirms Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $36.00 price target on the stock.

A number of other research firms also recently issued reports on FDMT. Morgan Stanley reduced their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Saturday, February 1st. Chardan Capital reiterated a “buy” rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $40.00 to $15.00 in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.25.

4D Molecular Therapeutics Stock Down 8.4 %

Shares of 4D Molecular Therapeutics stock opened at $5.97 on Monday. 4D Molecular Therapeutics has a fifty-two week low of $4.43 and a fifty-two week high of $36.25. The firm has a market cap of $275.99 million, a P/E ratio of -2.09 and a beta of 2.81. The business has a 50-day moving average price of $5.84 and a 200 day moving average price of $9.75.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC raised its stake in shares of 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock worth $1,241,000 after buying an additional 67,202 shares in the last quarter. Novo Holdings A S raised its position in 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after acquiring an additional 100,000 shares in the last quarter. nVerses Capital LLC acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter valued at about $40,000. Braidwell LP boosted its position in shares of 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after purchasing an additional 855,990 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after buying an additional 37,232 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.